1. DOP74 Comparative effectiveness of vedolizumab and ustekinumab in Crohn's Disease patients who failed anti-TNF treatment: Interrogating 1019 patients from the UK IBD BioResource. (21st January 2022) Authors: Desoki, R; Balendran, K; Kapizioni, C; Shawky, R; Parkes, M; Raine, T Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P554 Vedolizumab Associated quality of Life and inflammatory bowel disease control Upon Entering a subcutaneous switching program (VALUE) – Results from a multi-centre UK study. (21st January 2022) Authors: Lim, S; Gros Alcade, B; Lehmann, A; Lindsay, J; Gaya, D; Caulfield, L; Dhar, A; Ritchie, S; Limdi, J; Taylor, J; Raine, T; Balendran, K; Shuttleworth, E; Kwok, J; Cococcia, S; Murray, C; Walker, G; Aldridge, R; George, B; Colbert, R Journal: Journal of Crohn's and colitis Issue: Volume 16(2022)Supplement 1 Page Start: i499 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P668 Differential efficacy of biologic agents for Inflammatory Bowel Disease Unclassified and comparison with Ulcerative Colitis: a propensity score analysis of 4054 patients from the UK IBD BioResource. (30th January 2023) Authors: Kapizioni, C; Desoki, R; Balendran, K; Lam, D; Shawky, R; Pele, L; Parkes, M; Raine, T Journal: Journal of Crohn's and colitis Issue: Volume 17(2023)Supplement 1 Page Start: i800 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗